Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Sino Biological Invests Over 200M RMB to Establish New Subsidiaries in Taizhou and Suzhou, China.

Sino Biological is pleased to announce the formation of two new operationally-focused subsidiaries in China.

From Sino Biological Inc. 14 Mar 2022

Canadian scientist discusses about how society could better prepare for future pandemics

Aled Edwards is of two minds about medicine's response to COVID-19. On one hand, he notes, we had life-saving vaccines and therapies less than a year after the discovery of SARS-CoV-2. On the other, more than six million, and possibly as many as 18 million people have died, and global access to advances that can prevent and treat severe disease remains highly inequitable.

11 Mar 2022

Potent pan-β-CoV human monoclonal antibody has in vivo activity in multiple animal models

Researchers evaluated the efficacy of viral spike domain 2-specific human monoclonal antibodies delivered intranasally, against all beta coronaviruses in hamsters and mice.

11 Mar 2022

Study isolated largest panel of β-CoV broadly neutralizing antibodies to date

Researchers isolated a large panel of broadly neutralizing antibodies from COVID-19 recovered-vaccinated donors.

10 Mar 2022

Single dose of new drug nirsevimab provides safe protection against RSV in healthy infants

The new drug nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomized, placebo-controlled phase 3 clinical trial published in the New England Journal of Medicine.

9 Mar 2022

Effectiveness of mRNA vaccines, antibody treatment reduced by all three omicron subvariants

Only one currently authorized antibody treatment retains its activity against all Omicron subvariants, according to new research by scientists at Columbia University and the University of Hong Kong.

3 Mar 2022

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomized, placebo-controlled Phase 3 clinical trial.

3 Mar 2022

Intensive treatment for patients with Crohn's disease found to be safe

Intensive treatment for patients with Crohn's disease showed no safety differences compared to the current standard of care, according to a trial published in the journal Gastroenterology.

1 Mar 2022

U of U Health researchers lead a $22-million nationwide clinical trial for rare brain disorder

University of Utah Health researchers are leading a five-year, $22-million nationwide clinical trial for NMDA receptor encephalitis––a type of autoimmune encephalitis that prompts the immune system to mistakenly attack the brain, causing confusion, memory loss, seizures, and symptoms similar to bipolar disorder and other psychiatric conditions.

1 Mar 2022

Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model

Researchers found that an antiviral drug, was effective against SARS-CoV-2 variants, including the recently emerged Omicron variant, in Syrian hamsters.

1 Mar 2022

Study explores the boosting of SARS-CoV-2 adenovirus vaccine-induced immunity by capsid decoration

Researchers demonstrated that decorating the capsid surface of adenovirus vaccine vectors with a newly discovered protein superglue, DogTag/DogCatcher generates potent SARS-CoV-2-specific humoral and cellular immunity.

24 Feb 2022

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Multiple myeloma (MM) is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, investigators from Japan have recently found that a common component of amino acid transporters, CD98 heavy chain, represents an effective monoclonal antibody target in treating MM.

22 Feb 2022

Monoclonal Antibody News and Research

Further Reading

Sino Biological Invests Over 200M RMB to Establish New Subsidiaries in Taizhou and Suzhou, China.

Canadian scientist discusses about how society could better prepare for future pandemics

Potent pan-β-CoV human monoclonal antibody has in vivo activity in multiple animal models

Study isolated largest panel of β-CoV broadly neutralizing antibodies to date

Single dose of new drug nirsevimab provides safe protection against RSV in healthy infants

Effectiveness of mRNA vaccines, antibody treatment reduced by all three omicron subvariants

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Intensive treatment for patients with Crohn's disease found to be safe

U of U Health researchers lead a $22-million nationwide clinical trial for rare brain disorder

Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model

Study explores the boosting of SARS-CoV-2 adenovirus vaccine-induced immunity by capsid decoration

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Study explores the decline in viral load and immune response in COVID-19 patients

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

Ensitrelvir, a novel SARS-CoV-2 antiviral

SARS-CoV-2 variants are evolving increased infectivity and antibody escape, studies say

Study explores how the electrostatic charge of the SARS-CoV-2 spike protein has changed over time

Inside the tactical tug of war over the controversial Alzheimer’s drug

Human nose organoids provide better understanding of the first steps toward SARS-CoV-2 infection

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®